AIVITA BIOMEDICAL, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM
Phase 3
Not yet recruiting
- Conditions
- Primary Glioblastoma
- Interventions
- Biological: AV-GBM-1Biological: Autologous monocytes
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Aivita Biomedical, Inc.
- Target Recruit Count
- 672
- Registration Number
- NCT05100641
Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19
Phase 2
Completed
- Conditions
- COVID-19
- Interventions
- Biological: AV-COVID-19
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Aivita Biomedical, Inc.
- Target Recruit Count
- 145
- Registration Number
- NCT05007496
- Locations
- 🇮🇩
RSPAD Gatot Soebroto, Jakarta, Indonesia
Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Biological: AV-COVID-19Other: GM-CSF
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Aivita Biomedical, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04690387
- Locations
- 🇮🇩
Rumah Sakit Umum Pusat Dr. Kariadi, Semarang, Jawa Tengah, Indonesia
Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults
Phase 1
Withdrawn
- Conditions
- COVID-19
- Interventions
- Biological: AV-COVID-19
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Aivita Biomedical, Inc.
- Registration Number
- NCT04386252
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Aivita Biomedical, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03743298
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Jericho Rabago, Irvine, California, United States
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma
Phase 2
- Conditions
- Newly Diagnosed Glioblastoma
- Interventions
- Biological: AV-GBM-1
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Aivita Biomedical, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT03400917
- Locations
- 🇺🇸
Rutgers Cancer Institute, New Brunswick, New Jersey, United States
🇺🇸John Wayne Cancer Institute, Santa Monica, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas
Phase 2
- Conditions
- Stage III Ovarian CarcinomaFallopian Tube CarcinomaPrimary Peritoneal CarcinomaStage IV Ovarian Carcinoma
- Interventions
- Biological: MCBiological: AVOVA-1
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Aivita Biomedical, Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT02033616
- Locations
- 🇺🇸
Disney Family Cancer Center, Burbank, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Scripps Health, La Jolla, California, United States
© Copyright 2025. All Rights Reserved by MedPath